Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age

Pediatric Infectious Disease Journal

Volumn 33, Issue 6, 2014, Pages 630-636

  Greenberg, David P ^a,b   Robertson, Corwin A ^a   Landolfi, Victoria A ^a   Bhaumik, Amitabha ^a   Senders, Shelly D ^c   Decker, Michael D ^a,d  

^a SANOFI PASTEUR   (France)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Senders Pediatrics   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

children; immunogenicity; Influenza vaccine; safety

Indexed keywords

INFLUENZA VACCINE; QUADRIVALENT INFLUENZA VACCINE; UNCLASSIFIED DRUG; INACTIVATED VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; CHILD; CHILD SAFETY; CLINICAL ASSESSMENT; CONTROLLED STUDY; COUGHING; CRYING; DROWSINESS; DRUG FEVER; DRUG SAFETY; FEBRILE CONVULSION; FEMALE; FOLLOW UP; HEADACHE; HUMAN; IMMUNOGENICITY; INFANT; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; IRRITABILITY; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWELLING; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VOMITING; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; INFLUENZA, HUMAN; ORTHOMYXOVIRUS; PRESCHOOL CHILD;

ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; ORTHOMYXOVIRIDAE; UNITED STATES; VACCINES, INACTIVATED;

EID: 84901502872     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000254     Document Type: Article

References (23)

1. Centers for Disease Control. Update: influenza activity-United States 2011-12 season and composition of the 2012-13 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2012;61:414-420.
2. Fiore AE Uyeki TM Broder K et al.; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on I mmunization Practices (ACIP) 2010. MMWR Recomm Rep. 2010;59(RR-8):1-62.
3. Rota PA Wallis TR Harmon MW et al. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 1990;175:59-68. (Pubitemid 20093061)
4. Glezen WP Schmier JK Kuehn CM et al. The burden of influenza B: a structured literature review. Am J Public Health. 2013;103:e43-e51.
5. Centers for Disease Control. Past weekly surveillance reports 2013. Available at: http://www.cdc.gov/flu/weekly/pastreports.htm. Accessed January 8 2013.
6. Belo ngia EA Kieke BA Donahue JG et al.; Marshfield Influenza Study Group. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis. 2009;199:159-167.
7. Skowronski DM De Serres G Dickinson J et al. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada 2006-2007. J Infect Dis. 2009;199:168-179.
8. Reed C Meltzer MI Finelli L et al. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine. 2012;30:1993-1998.
9. Poehling KA Edwards KM Weinberg GA et al.; New Vaccine Surveillance Network. The underrecognized burden of influenza in young children. N Engl J Med. 2006;355:31-40.
10. Grant KA Carville K Fielding JE et al. High proportion of influenza B characterises the 2008 influenza season in Victoria. Commun Dis Intell Q Rep. 2009;33:328-336.
11. Olson DR Heffernan RT Paladini M et al. Monitoring the impact of influenza by age: emergency department fever and respiratory complaint surveillance in New York City. PLoS Med. 2007; 4:e247.
12. Ambrose CS Levin MJ The rationale for quadrivalent influenza vaccines Hum Vaccin Immunother 2012 8 81-88.
13. Neuzil KM Dupont WD Wright PF e t al. Efficacy of inactivated and coldadapted vaccines against influenza A infection 1985 to 1990: the pediatric experience. Pediatr Infect Dis J. 2001;20:733-740.
14. Treanor JJ Talbot HK Ohmit SE et al.; US Flu-VE Network. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis. 2012;55:951-959.
15. Mitchell DK Ruben FL Gravenstein S. Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004. Pediatr Infect Dis J. 2005;24:925-927. (Pubitemid 41475932)
16. Lina B Fletcher MA V alette M et al. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity in Children Adults and the Elderly. Bi ologicals. 2000;28:95-103.
17. Gonzalez M Pirez MC Ward E et al. Safety and immunogenicity of a paediatric presentation of an influenza vaccine. Arch Dis Child. 2000;83:488-491.
18. France EK Glanz JM Xu S et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch Pediatr Adolesc Med. 2004;158:1031-1036. (Pubitemid 39458490)
19. Block SL Falloon J Hirschfield JA et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J. 2012;31:745-751.
20. Block SL Yi T Sheldon E et al. A randomized double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine. 2011;29:9391-9397.
21. Domachowske JB Pankow-Cul ot H Bautista M et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis. 2013;207: 1878-1887.
22. Greenberg DP Robertson CA Noss MJ et al. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013;31:770-776.
23. Greenberg DP Robertson C Talbot HK et al. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine (QIV) containing two A and two B strains among persons 65 years of age (Abstract 544 presented). In: 49th Annual Meeting of the Infectious Diseases Society of America (IDSA). Boston MA: Infectious Diseases Society of America; 2011.